Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dazodalibep · VIB-4920, MEDI-4920

Fusion protein · developed by Amgen

Phase 3 Most advanced trial (none active)
AMGN Developer
1 Registered trials

What is Dazodalibep?

Dazodalibep is a BAFF receptor fusion protein that binds and neutralizes B-cell activating factor (BAFF). It is being studied in Sjogren's Syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VIB-4920, MEDI-4920
Drug type
Fusion protein
Therapy area
Immunology
Developer
Amgen (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
HN5US76BWF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06104124 Phase 3 Sjogren's Syndrome Completed AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Sjogren's Syndrome

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Follow AMGN, the company behind Dazodalibep

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.